Nasdaq
$3.99▼ 0.37%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $239.9MShares out 60.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 10.9After-hours26.10.10 06:26SCHEDULE 13G/AOwnership#●●●
Vanda Pharmaceuticals Inc.
Millennium Management LLC, its affiliated entities, and Israel A. Englander have filed a Schedule 13G regarding their beneficial ownership of Vanda Pharmaceuticals Inc. common stock. This filing serves as a formal confirmation of their joint holdings in the company.…more
$3.99-0.37%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.19After-hours26.08.20 07:32SCHEDULE 13GOwnership
Vanda Pharmaceuticals Inc.
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have entered into a joint filing agreement regarding the Schedule 13G disclosure for their beneficial ownership of Vanda Pharmaceuticals Inc. common stock. Dated August 18, 2026, this agreement ensures the joint reporting of their shareholdings in compliance with Rule 13d-1(k) of the Securities Exchange Act.…more
$3.99-0.37%vs prev closeView filingShare - 8.13Pre-market26.08.13 22:22SCHEDULE 13GOwnership
Vanda Pharmaceuticals Inc.
AQR Capital Management LLC has filed a Schedule 13G, disclosing that it holds more than 5% of the outstanding shares of Vanda Pharmaceuticals Inc. This filing confirms that the institutional investor has crossed the significant ownership threshold for the company.…more
$3.99-0.37%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15Pre-market26.10.15 21:47Bullish#●●●#●●●
Vanda Pharmaceuticals Anxiety Drug Fails Phase 3 Trial
Vanda Pharmaceuticals' anxiety treatment candidate VQW-765 failed to meet its primary endpoint in a Phase 3 clinical trial. The drug showed no significant benefit over a placebo, failing to replicate promising results from earlier Phase 2 testing.…more
$3.99-0.37%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.14After-hours26.10.15 06:03
●●●●●●●● ●●●●● ●●●●●●
Vanda Pharmaceuticals announced that its Phase III clinical trial for VQW-765 in adults with social anxiety disorder did not meet its primary endpoint. While the drug was found to be safe and well-tolerated, the failure to achieve primary efficacy goals poses a setback for the program.…more
$3.99-0.37%vs prev closeShareBenzinga - 9.30Pre-market26.09.30 22:10
●●●●●●●● ●●●●● ●●●●●●
Vanda Pharmaceuticals announced that its drug HETLIOZ met primary endpoints in a Phase 3 trial for Delayed Sleep-Wake Phase Disorder by significantly advancing sleep onset. The company plans to submit these results to the FDA to seek regulatory approval for this new indication.…more
$3.99-0.37%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report